FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver

FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver Xinqiang Huang , Chaofeng Yang , Yongde Luo , Chengliu Jin , Fen Wang and Wallace L. McKeehan From the Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2007-10, Vol.56 (10), p.2501-2510
Hauptverfasser: Huang, Xinqiang, Yang, Chaofeng, Luo, Yongde, Jin, Chengliu, Wang, Fen, McKeehan, Wallace L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2510
container_issue 10
container_start_page 2501
container_title Diabetes (New York, N.Y.)
container_volume 56
creator Huang, Xinqiang
Yang, Chaofeng
Luo, Yongde
Jin, Chengliu
Wang, Fen
McKeehan, Wallace L
description FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver Xinqiang Huang , Chaofeng Yang , Yongde Luo , Chengliu Jin , Fen Wang and Wallace L. McKeehan From the Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, Texas Address correspondence and reprint requests to Wallace L. McKeehan, PhD, Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M Health Science Center, 2121 W. Holcombe Blvd., Houston, TX 77030. E-mail: wmckeehan{at}ibt.tamhsc.edu Abstract OBJECTIVE— Fibroblast growth factor (FGF) family signaling largely controls cellular homeostasis through short-range intercell paracrine communication. Recently FGF15/19, 21, and 23 have been implicated in endocrine control of metabolic homeostasis. The identity and location of the FGF receptor isotypes that mediate these effects are unclear. The objective was to determine the role of FGFR4, an isotype that has been proposed to mediate an ileal FGF15/19 to hepatocyte FGFR4 axis in cholesterol homeostasis, in metabolic homeostasis in vivo. RESEARCH DESIGN AND METHODS— FGFR4 −/− mice—mice overexpressing constitutively active hepatic FGFR4—and FGFR4 −/− with constitutively active hepatic FGFR4 restored in the liver were subjected to a normal and a chronic high-fat diet sufficient to result in obesity. Systemic and liver-specific metabolic phenotypes were then characterized. RESULTS— FGFR4-deficient mice on a normal diet exhibited features of metabolic syndrome that include increased mass of white adipose tissue, hyperlipidemia, glucose intolerance, and insulin resistance, in addition to hypercholesterolemia. Surprisingly, the FGFR4 deficiency alleviated high-fat diet–induced fatty liver in obese mice, which is also a correlate of metabolic syndrome. Restoration of FGFR4, specifically in hepatocytes of FGFR4-deficient mice, decreased plasma lipid levels and restored the high-fat diet–induced fatty liver but failed to restore glucose tolerance and sensitivity to insulin. CONCLUSIONS— FGFR4 plays essential roles in systemic lipid and glucose homeostasis. FGFR4 activity in hepatocytes that normally serves to prevent systemic hyperlipidemia paradoxically underlies the fatty liver disease associated with chronic high-fat intake and obesity. FGF, fibroblast growth factor FXR, farnesoid X receptor G6Pase, glucose-6-phosphatase NAFLD, nonalcoholic fatty liver disease PP
doi_str_mv 10.2337/db07-0648
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_68328360</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A170036748</galeid><sourcerecordid>A170036748</sourcerecordid><originalsourceid>FETCH-LOGICAL-c627t-c3c87d9cdb0be2d70ad3a43b6e6d2e73e726e8d2cd23a90daf4780a6ac198cd13</originalsourceid><addsrcrecordid>eNpt0t1q2zAUB3AxNta028VeYJjBCoO504cj2ZclW9JAoKOssDshS8euiiOnktwtd3uHveGeZPISCB1BFxLid8TR4Y_QG4IvKGPik6mxyDEvymdoQipW5YyK78_RBGNCcyIqcYJOQ7jHGPO0XqITIjgvaMEmqJkv5jdF9tXDI7gYsqvtBnxnN9bA2qpMOZMtXRg667IbCDZE5TRk9RCzW2dGCanGtnf5XMXss4X459fvpTODBpOlq7jNVvYR_Cv0olFdgNf7_Qzdzr98m13lq-vFcna5yjWnIuaa6VKYSqcP1UCNwMowVbCaAzcUBANBOZSGakOZqrBRTSFKrLjSpCq1IewMne_e3fj-YYAQ5doGDV2nHPRDkLxktGQcJ_juP3jfD96l3iQlvBBClFVC-Q61qgNpXdNHr3QLDrzqegeNTdeXRGDMuCjK5C-O-LTGYeqjBR-eFCQT4Wds1RCCLBerpzY_ZnXfddCCTGOcXR99W_s-BA-N3Hi7Vn4rCZZjbOQYGznGJtm3-2kM9RrMQe5zksD7PVBBq67xKQY2HFxFpoKRaXIfd-4uZeKH9SCNVTVECIfDlP_rYIoJ-wsPZ9ci</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216477789</pqid></control><display><type>article</type><title>FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Huang, Xinqiang ; Yang, Chaofeng ; Luo, Yongde ; Jin, Chengliu ; Wang, Fen ; McKeehan, Wallace L</creator><creatorcontrib>Huang, Xinqiang ; Yang, Chaofeng ; Luo, Yongde ; Jin, Chengliu ; Wang, Fen ; McKeehan, Wallace L</creatorcontrib><description>FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver Xinqiang Huang , Chaofeng Yang , Yongde Luo , Chengliu Jin , Fen Wang and Wallace L. McKeehan From the Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&amp;M Health Science Center, Houston, Texas Address correspondence and reprint requests to Wallace L. McKeehan, PhD, Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&amp;M Health Science Center, 2121 W. Holcombe Blvd., Houston, TX 77030. E-mail: wmckeehan{at}ibt.tamhsc.edu Abstract OBJECTIVE— Fibroblast growth factor (FGF) family signaling largely controls cellular homeostasis through short-range intercell paracrine communication. Recently FGF15/19, 21, and 23 have been implicated in endocrine control of metabolic homeostasis. The identity and location of the FGF receptor isotypes that mediate these effects are unclear. The objective was to determine the role of FGFR4, an isotype that has been proposed to mediate an ileal FGF15/19 to hepatocyte FGFR4 axis in cholesterol homeostasis, in metabolic homeostasis in vivo. RESEARCH DESIGN AND METHODS— FGFR4 −/− mice—mice overexpressing constitutively active hepatic FGFR4—and FGFR4 −/− with constitutively active hepatic FGFR4 restored in the liver were subjected to a normal and a chronic high-fat diet sufficient to result in obesity. Systemic and liver-specific metabolic phenotypes were then characterized. RESULTS— FGFR4-deficient mice on a normal diet exhibited features of metabolic syndrome that include increased mass of white adipose tissue, hyperlipidemia, glucose intolerance, and insulin resistance, in addition to hypercholesterolemia. Surprisingly, the FGFR4 deficiency alleviated high-fat diet–induced fatty liver in obese mice, which is also a correlate of metabolic syndrome. Restoration of FGFR4, specifically in hepatocytes of FGFR4-deficient mice, decreased plasma lipid levels and restored the high-fat diet–induced fatty liver but failed to restore glucose tolerance and sensitivity to insulin. CONCLUSIONS— FGFR4 plays essential roles in systemic lipid and glucose homeostasis. FGFR4 activity in hepatocytes that normally serves to prevent systemic hyperlipidemia paradoxically underlies the fatty liver disease associated with chronic high-fat intake and obesity. FGF, fibroblast growth factor FXR, farnesoid X receptor G6Pase, glucose-6-phosphatase NAFLD, nonalcoholic fatty liver disease PPAR, peroxisome proliferator–activated receptor SCD, stearoyl-CoA desaturase Footnotes Published ahead of print at http://diabetes.diabetesjournals.org on 30 July 2007. DOI: 10.2337/db07-0648. Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/db07-0648 . The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Accepted July 18, 2007. Received May 14, 2007. DIABETES</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db07-0648</identifier><identifier>PMID: 17664243</identifier><identifier>CODEN: DIAEAZ</identifier><language>eng</language><publisher>Alexandria, VA: American Diabetes Association</publisher><subject>Acids ; Adipose Tissue - pathology ; Animals ; Bile ; Biological and medical sciences ; Blood Glucose - metabolism ; Body fat ; Body Weight ; Cholesterol ; Diabetes ; Diabetes. Impaired glucose tolerance ; Diet ; Dietary Fats - adverse effects ; Disorders of blood lipids. Hyperlipoproteinemia ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Fatty liver ; Fatty Liver - genetics ; Fatty Liver - metabolism ; Fatty Liver - pathology ; Fibroblast growth factors ; Fibroblasts ; Gastroenterology. Liver. Pancreas. Abdomen ; Gene Expression Regulation ; Glucose ; Glucose - metabolism ; Growth factors ; Health aspects ; Heparan sulfate ; Homeostasis ; Hyperlipidemia ; Hyperlipidemias - genetics ; Hyperlipidemias - prevention &amp; control ; Insulin - blood ; Insulin Resistance ; Lipids ; Lipids - physiology ; Liver - anatomy &amp; histology ; Liver - pathology ; Liver - physiopathology ; Liver diseases ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Medical sciences ; Metabolic diseases ; Metabolic syndrome ; Mice ; Mice, Knockout ; Mice, Transgenic ; Nutrition research ; Obesity ; Organ Size ; Other diseases. Semiology ; Prevention ; Receptor, Fibroblast Growth Factor, Type 4 - deficiency ; Receptor, Fibroblast Growth Factor, Type 4 - genetics ; Receptor, Fibroblast Growth Factor, Type 4 - physiology ; Research design ; RNA, Messenger - genetics</subject><ispartof>Diabetes (New York, N.Y.), 2007-10, Vol.56 (10), p.2501-2510</ispartof><rights>2007 INIST-CNRS</rights><rights>COPYRIGHT 2007 American Diabetes Association</rights><rights>Copyright American Diabetes Association Oct 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c627t-c3c87d9cdb0be2d70ad3a43b6e6d2e73e726e8d2cd23a90daf4780a6ac198cd13</citedby><cites>FETCH-LOGICAL-c627t-c3c87d9cdb0be2d70ad3a43b6e6d2e73e726e8d2cd23a90daf4780a6ac198cd13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=19157315$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17664243$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Xinqiang</creatorcontrib><creatorcontrib>Yang, Chaofeng</creatorcontrib><creatorcontrib>Luo, Yongde</creatorcontrib><creatorcontrib>Jin, Chengliu</creatorcontrib><creatorcontrib>Wang, Fen</creatorcontrib><creatorcontrib>McKeehan, Wallace L</creatorcontrib><title>FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver</title><title>Diabetes (New York, N.Y.)</title><addtitle>Diabetes</addtitle><description>FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver Xinqiang Huang , Chaofeng Yang , Yongde Luo , Chengliu Jin , Fen Wang and Wallace L. McKeehan From the Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&amp;M Health Science Center, Houston, Texas Address correspondence and reprint requests to Wallace L. McKeehan, PhD, Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&amp;M Health Science Center, 2121 W. Holcombe Blvd., Houston, TX 77030. E-mail: wmckeehan{at}ibt.tamhsc.edu Abstract OBJECTIVE— Fibroblast growth factor (FGF) family signaling largely controls cellular homeostasis through short-range intercell paracrine communication. Recently FGF15/19, 21, and 23 have been implicated in endocrine control of metabolic homeostasis. The identity and location of the FGF receptor isotypes that mediate these effects are unclear. The objective was to determine the role of FGFR4, an isotype that has been proposed to mediate an ileal FGF15/19 to hepatocyte FGFR4 axis in cholesterol homeostasis, in metabolic homeostasis in vivo. RESEARCH DESIGN AND METHODS— FGFR4 −/− mice—mice overexpressing constitutively active hepatic FGFR4—and FGFR4 −/− with constitutively active hepatic FGFR4 restored in the liver were subjected to a normal and a chronic high-fat diet sufficient to result in obesity. Systemic and liver-specific metabolic phenotypes were then characterized. RESULTS— FGFR4-deficient mice on a normal diet exhibited features of metabolic syndrome that include increased mass of white adipose tissue, hyperlipidemia, glucose intolerance, and insulin resistance, in addition to hypercholesterolemia. Surprisingly, the FGFR4 deficiency alleviated high-fat diet–induced fatty liver in obese mice, which is also a correlate of metabolic syndrome. Restoration of FGFR4, specifically in hepatocytes of FGFR4-deficient mice, decreased plasma lipid levels and restored the high-fat diet–induced fatty liver but failed to restore glucose tolerance and sensitivity to insulin. CONCLUSIONS— FGFR4 plays essential roles in systemic lipid and glucose homeostasis. FGFR4 activity in hepatocytes that normally serves to prevent systemic hyperlipidemia paradoxically underlies the fatty liver disease associated with chronic high-fat intake and obesity. FGF, fibroblast growth factor FXR, farnesoid X receptor G6Pase, glucose-6-phosphatase NAFLD, nonalcoholic fatty liver disease PPAR, peroxisome proliferator–activated receptor SCD, stearoyl-CoA desaturase Footnotes Published ahead of print at http://diabetes.diabetesjournals.org on 30 July 2007. DOI: 10.2337/db07-0648. Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/db07-0648 . The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Accepted July 18, 2007. Received May 14, 2007. DIABETES</description><subject>Acids</subject><subject>Adipose Tissue - pathology</subject><subject>Animals</subject><subject>Bile</subject><subject>Biological and medical sciences</subject><subject>Blood Glucose - metabolism</subject><subject>Body fat</subject><subject>Body Weight</subject><subject>Cholesterol</subject><subject>Diabetes</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diet</subject><subject>Dietary Fats - adverse effects</subject><subject>Disorders of blood lipids. Hyperlipoproteinemia</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Fatty liver</subject><subject>Fatty Liver - genetics</subject><subject>Fatty Liver - metabolism</subject><subject>Fatty Liver - pathology</subject><subject>Fibroblast growth factors</subject><subject>Fibroblasts</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Gene Expression Regulation</subject><subject>Glucose</subject><subject>Glucose - metabolism</subject><subject>Growth factors</subject><subject>Health aspects</subject><subject>Heparan sulfate</subject><subject>Homeostasis</subject><subject>Hyperlipidemia</subject><subject>Hyperlipidemias - genetics</subject><subject>Hyperlipidemias - prevention &amp; control</subject><subject>Insulin - blood</subject><subject>Insulin Resistance</subject><subject>Lipids</subject><subject>Lipids - physiology</subject><subject>Liver - anatomy &amp; histology</subject><subject>Liver - pathology</subject><subject>Liver - physiopathology</subject><subject>Liver diseases</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Metabolic syndrome</subject><subject>Mice</subject><subject>Mice, Knockout</subject><subject>Mice, Transgenic</subject><subject>Nutrition research</subject><subject>Obesity</subject><subject>Organ Size</subject><subject>Other diseases. Semiology</subject><subject>Prevention</subject><subject>Receptor, Fibroblast Growth Factor, Type 4 - deficiency</subject><subject>Receptor, Fibroblast Growth Factor, Type 4 - genetics</subject><subject>Receptor, Fibroblast Growth Factor, Type 4 - physiology</subject><subject>Research design</subject><subject>RNA, Messenger - genetics</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0t1q2zAUB3AxNta028VeYJjBCoO504cj2ZclW9JAoKOssDshS8euiiOnktwtd3uHveGeZPISCB1BFxLid8TR4Y_QG4IvKGPik6mxyDEvymdoQipW5YyK78_RBGNCcyIqcYJOQ7jHGPO0XqITIjgvaMEmqJkv5jdF9tXDI7gYsqvtBnxnN9bA2qpMOZMtXRg667IbCDZE5TRk9RCzW2dGCanGtnf5XMXss4X459fvpTODBpOlq7jNVvYR_Cv0olFdgNf7_Qzdzr98m13lq-vFcna5yjWnIuaa6VKYSqcP1UCNwMowVbCaAzcUBANBOZSGakOZqrBRTSFKrLjSpCq1IewMne_e3fj-YYAQ5doGDV2nHPRDkLxktGQcJ_juP3jfD96l3iQlvBBClFVC-Q61qgNpXdNHr3QLDrzqegeNTdeXRGDMuCjK5C-O-LTGYeqjBR-eFCQT4Wds1RCCLBerpzY_ZnXfddCCTGOcXR99W_s-BA-N3Hi7Vn4rCZZjbOQYGznGJtm3-2kM9RrMQe5zksD7PVBBq67xKQY2HFxFpoKRaXIfd-4uZeKH9SCNVTVECIfDlP_rYIoJ-wsPZ9ci</recordid><startdate>20071001</startdate><enddate>20071001</enddate><creator>Huang, Xinqiang</creator><creator>Yang, Chaofeng</creator><creator>Luo, Yongde</creator><creator>Jin, Chengliu</creator><creator>Wang, Fen</creator><creator>McKeehan, Wallace L</creator><general>American Diabetes Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8GL</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20071001</creationdate><title>FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver</title><author>Huang, Xinqiang ; Yang, Chaofeng ; Luo, Yongde ; Jin, Chengliu ; Wang, Fen ; McKeehan, Wallace L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c627t-c3c87d9cdb0be2d70ad3a43b6e6d2e73e726e8d2cd23a90daf4780a6ac198cd13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Acids</topic><topic>Adipose Tissue - pathology</topic><topic>Animals</topic><topic>Bile</topic><topic>Biological and medical sciences</topic><topic>Blood Glucose - metabolism</topic><topic>Body fat</topic><topic>Body Weight</topic><topic>Cholesterol</topic><topic>Diabetes</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diet</topic><topic>Dietary Fats - adverse effects</topic><topic>Disorders of blood lipids. Hyperlipoproteinemia</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Fatty liver</topic><topic>Fatty Liver - genetics</topic><topic>Fatty Liver - metabolism</topic><topic>Fatty Liver - pathology</topic><topic>Fibroblast growth factors</topic><topic>Fibroblasts</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Gene Expression Regulation</topic><topic>Glucose</topic><topic>Glucose - metabolism</topic><topic>Growth factors</topic><topic>Health aspects</topic><topic>Heparan sulfate</topic><topic>Homeostasis</topic><topic>Hyperlipidemia</topic><topic>Hyperlipidemias - genetics</topic><topic>Hyperlipidemias - prevention &amp; control</topic><topic>Insulin - blood</topic><topic>Insulin Resistance</topic><topic>Lipids</topic><topic>Lipids - physiology</topic><topic>Liver - anatomy &amp; histology</topic><topic>Liver - pathology</topic><topic>Liver - physiopathology</topic><topic>Liver diseases</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Metabolic syndrome</topic><topic>Mice</topic><topic>Mice, Knockout</topic><topic>Mice, Transgenic</topic><topic>Nutrition research</topic><topic>Obesity</topic><topic>Organ Size</topic><topic>Other diseases. Semiology</topic><topic>Prevention</topic><topic>Receptor, Fibroblast Growth Factor, Type 4 - deficiency</topic><topic>Receptor, Fibroblast Growth Factor, Type 4 - genetics</topic><topic>Receptor, Fibroblast Growth Factor, Type 4 - physiology</topic><topic>Research design</topic><topic>RNA, Messenger - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Xinqiang</creatorcontrib><creatorcontrib>Yang, Chaofeng</creatorcontrib><creatorcontrib>Luo, Yongde</creatorcontrib><creatorcontrib>Jin, Chengliu</creatorcontrib><creatorcontrib>Wang, Fen</creatorcontrib><creatorcontrib>McKeehan, Wallace L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: High School</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Xinqiang</au><au>Yang, Chaofeng</au><au>Luo, Yongde</au><au>Jin, Chengliu</au><au>Wang, Fen</au><au>McKeehan, Wallace L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><addtitle>Diabetes</addtitle><date>2007-10-01</date><risdate>2007</risdate><volume>56</volume><issue>10</issue><spage>2501</spage><epage>2510</epage><pages>2501-2510</pages><issn>0012-1797</issn><eissn>1939-327X</eissn><coden>DIAEAZ</coden><abstract>FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver Xinqiang Huang , Chaofeng Yang , Yongde Luo , Chengliu Jin , Fen Wang and Wallace L. McKeehan From the Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&amp;M Health Science Center, Houston, Texas Address correspondence and reprint requests to Wallace L. McKeehan, PhD, Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&amp;M Health Science Center, 2121 W. Holcombe Blvd., Houston, TX 77030. E-mail: wmckeehan{at}ibt.tamhsc.edu Abstract OBJECTIVE— Fibroblast growth factor (FGF) family signaling largely controls cellular homeostasis through short-range intercell paracrine communication. Recently FGF15/19, 21, and 23 have been implicated in endocrine control of metabolic homeostasis. The identity and location of the FGF receptor isotypes that mediate these effects are unclear. The objective was to determine the role of FGFR4, an isotype that has been proposed to mediate an ileal FGF15/19 to hepatocyte FGFR4 axis in cholesterol homeostasis, in metabolic homeostasis in vivo. RESEARCH DESIGN AND METHODS— FGFR4 −/− mice—mice overexpressing constitutively active hepatic FGFR4—and FGFR4 −/− with constitutively active hepatic FGFR4 restored in the liver were subjected to a normal and a chronic high-fat diet sufficient to result in obesity. Systemic and liver-specific metabolic phenotypes were then characterized. RESULTS— FGFR4-deficient mice on a normal diet exhibited features of metabolic syndrome that include increased mass of white adipose tissue, hyperlipidemia, glucose intolerance, and insulin resistance, in addition to hypercholesterolemia. Surprisingly, the FGFR4 deficiency alleviated high-fat diet–induced fatty liver in obese mice, which is also a correlate of metabolic syndrome. Restoration of FGFR4, specifically in hepatocytes of FGFR4-deficient mice, decreased plasma lipid levels and restored the high-fat diet–induced fatty liver but failed to restore glucose tolerance and sensitivity to insulin. CONCLUSIONS— FGFR4 plays essential roles in systemic lipid and glucose homeostasis. FGFR4 activity in hepatocytes that normally serves to prevent systemic hyperlipidemia paradoxically underlies the fatty liver disease associated with chronic high-fat intake and obesity. FGF, fibroblast growth factor FXR, farnesoid X receptor G6Pase, glucose-6-phosphatase NAFLD, nonalcoholic fatty liver disease PPAR, peroxisome proliferator–activated receptor SCD, stearoyl-CoA desaturase Footnotes Published ahead of print at http://diabetes.diabetesjournals.org on 30 July 2007. DOI: 10.2337/db07-0648. Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/db07-0648 . The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Accepted July 18, 2007. Received May 14, 2007. DIABETES</abstract><cop>Alexandria, VA</cop><pub>American Diabetes Association</pub><pmid>17664243</pmid><doi>10.2337/db07-0648</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0012-1797
ispartof Diabetes (New York, N.Y.), 2007-10, Vol.56 (10), p.2501-2510
issn 0012-1797
1939-327X
language eng
recordid cdi_proquest_miscellaneous_68328360
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Acids
Adipose Tissue - pathology
Animals
Bile
Biological and medical sciences
Blood Glucose - metabolism
Body fat
Body Weight
Cholesterol
Diabetes
Diabetes. Impaired glucose tolerance
Diet
Dietary Fats - adverse effects
Disorders of blood lipids. Hyperlipoproteinemia
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Fatty liver
Fatty Liver - genetics
Fatty Liver - metabolism
Fatty Liver - pathology
Fibroblast growth factors
Fibroblasts
Gastroenterology. Liver. Pancreas. Abdomen
Gene Expression Regulation
Glucose
Glucose - metabolism
Growth factors
Health aspects
Heparan sulfate
Homeostasis
Hyperlipidemia
Hyperlipidemias - genetics
Hyperlipidemias - prevention & control
Insulin - blood
Insulin Resistance
Lipids
Lipids - physiology
Liver - anatomy & histology
Liver - pathology
Liver - physiopathology
Liver diseases
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Medical sciences
Metabolic diseases
Metabolic syndrome
Mice
Mice, Knockout
Mice, Transgenic
Nutrition research
Obesity
Organ Size
Other diseases. Semiology
Prevention
Receptor, Fibroblast Growth Factor, Type 4 - deficiency
Receptor, Fibroblast Growth Factor, Type 4 - genetics
Receptor, Fibroblast Growth Factor, Type 4 - physiology
Research design
RNA, Messenger - genetics
title FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T14%3A33%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FGFR4%20Prevents%20Hyperlipidemia%20and%20Insulin%20Resistance%20but%20Underlies%20High-Fat%20Diet%E2%80%93Induced%20Fatty%20Liver&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=Huang,%20Xinqiang&rft.date=2007-10-01&rft.volume=56&rft.issue=10&rft.spage=2501&rft.epage=2510&rft.pages=2501-2510&rft.issn=0012-1797&rft.eissn=1939-327X&rft.coden=DIAEAZ&rft_id=info:doi/10.2337/db07-0648&rft_dat=%3Cgale_proqu%3EA170036748%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=216477789&rft_id=info:pmid/17664243&rft_galeid=A170036748&rfr_iscdi=true